BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 12494883)

  • 1. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.
    Minev BR; Guo F; Gueorguieva I; Kaiser HE
    In Vivo; 2002; 16(6):405-15. PubMed ID: 12494883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer vaccines: an update.
    Hipp JD; Hipp JA; Lyday BW; Minev BR
    In Vivo; 2000; 14(5):571-85. PubMed ID: 11125541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
    Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
    Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic approaches to breast cancer treatment.
    Sabel MS; Nehs MA
    Surg Oncol Clin N Am; 2005 Jan; 14(1):1-31, v. PubMed ID: 15541997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
    Yuan S; Shi C; Liu L; Han W
    Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer vaccines: current status.
    Hwang LC; Fein S; Levitsky H; Nelson WG
    Semin Oncol; 1999 Apr; 26(2):192-201. PubMed ID: 10597730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF; Drake CG
    Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer vaccines: promise for the future or pipe dream?
    Mittendorf EA; Peoples GE; Singletary SE
    Cancer; 2007 Oct; 110(8):1677-86. PubMed ID: 17763371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New trends in the development of cancer vaccines.
    Minev BR; Chavez FL; Mitchell MS
    In Vivo; 1998; 12(6):629-38. PubMed ID: 9891226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer vaccines: a critical review on clinical impact.
    Bitton RJ
    Curr Opin Mol Ther; 2004 Feb; 6(1):17-26. PubMed ID: 15011777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunology and breast cancer: therapeutic cancer vaccines.
    Curigliano G; Rescigno M; Goldhirsch A
    Breast; 2007 Dec; 16 Suppl 2():S20-6. PubMed ID: 17706425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunotherapy of prostate and bladder cancer.
    Totterman TH; Loskog A; Essand M
    BJU Int; 2005 Oct; 96(5):728-35. PubMed ID: 16144528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic vaccines for prostate cancer: a review of clinical data.
    Arlen PM; Gulley JL
    Curr Opin Investig Drugs; 2005 Jun; 6(6):592-6. PubMed ID: 15988910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccines for the treatment of prostate cancer.
    Alam S; McNeel DG
    Expert Rev Vaccines; 2010 Jul; 9(7):731-45. PubMed ID: 20624047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
    Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine therapy for cancer: fact or fiction?
    Odunsi K; Lele S; Savalgi R
    Surg Technol Int; 2004; 13():39-47. PubMed ID: 15744673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
    Acres B
    J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.